Free tool
FAERS Monitor: Zituvio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211566 or its brand name (Zituvio, Sitagliptin). Reports on generic versions are filed under their own applications.
Reports
10,989
Serious
10,521
96% of reports
Hospitalization
6,430
Death reported
1,161
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- acute kidney injury913
- diarrhoea621
- nausea561
- general physical health deterioration553
- fatigue536
- dyspnoea534
- vomiting524
- lactic acidosis495
- drug interaction446
- drug ineffective402
- off label use390
- anaemia389
- hypoglycaemia382
- dizziness373
- fall340
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 8 |
| 2008 | 26 |
| 2009 | 48 |
| 2010 | 195 |
| 2011 | 141 |
| 2012 | 115 |
| 2013 | 191 |
| 2014 | 225 |
| 2015 | 356 |
| 2016 | 432 |
| 2017 | 520 |
| 2018 | 799 |
| 2019 | 801 |
| 2020 | 996 |
| 2021 | 959 |
| 2022 | 1,025 |
| 2023 | 874 |
| 2024 | 1,057 |
| 2025 | 1,201 |
| 2026 | 1,020 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,170 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lactic acidosisSignal | 495 | 29.7 | 27.2 | 13,506 |
| hypoglycaemiaSignal | 382 | 15.2 | 13.8 | 5,020 |
| acute kidney injurySignal | 913 | 11.5 | 10.8 | 8,737 |
| general physical health deteriorationSignal | 553 | 9.2 | 8.5 | 4,029 |
| drug interactionSignal | 446 | 5.4 | 4.9 | 1,599 |
| anaemiaSignal | 389 | 3.9 | 3.5 | 845 |
| vomitingSignal | 524 | 2.1 | 2.0 | 322 |
| fall | 340 | 2.0 | 1.8 | 160 |
| diarrhoea | 621 | 1.8 | 1.7 | 246 |
| dyspnoea | 534 | 1.8 | 1.7 | 196 |
| dizziness | 373 | 1.4 | 1.3 | 49 |
| nausea | 561 | 1.4 | 1.3 | 54 |
| fatigue | 536 | 1.3 | 1.2 | 42 |
| off label use | 390 | 0.9 | 0.8 | 10 |
| drug ineffective | 402 | 0.6 | 0.5 | 127 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.